Aryl Tricyclic STING Agonists for Cross-Species Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current STING agonists, such as DMXAA, fail to effectively activate the human STING protein, limiting their efficacy in cancer immunotherapy, despite showing promise in murine models, and there is a need for compounds that can activate both human and murine STING proteins to induce interferon-β and cytokine production.
Innovation Solution
Development of aryl tricyclic compounds that act as STING agonists, capable of binding to and activating both human and murine STING proteins, thereby inducing interferon-β and cytokine production, enhancing tumor-specific T cell activation and immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DMXAA is used to activate STING protein, then tumor growth is inhibited in murine models, but it fails to activate human STING protein
Solution Approach 1:
The patent modifies the chemical structure parameters of STING agonists by introducing specific substituents at defined positions in the tricyclic core structure. This structural parameter change enables the compound to accommodate both human and murine STING protein binding requirements, resolving the species-specific activity limitation of DMXAA.
Solution Approach 2:
The invention creates a composite molecular structure combining a tricyclic core with specific aromatic substituents and side chains. This composite structure integrates multiple functional elements that collectively enable broad-spectrum STING activation across species barriers while maintaining potent immunostimulatory activity.
2Adaptability or versatility
If cyclic dinucleotides are used to activate STING, then both murine and human STING are activated, but the structural complexity increases
Solution Approach 1:
The patent simplifies the molecular structure by changing from complex cyclic dinucleotide frameworks to a more compact tricyclic architecture with defined substituent patterns. This parameter change maintains cross-species STING activation capability while reducing structural complexity and improving drug-like properties.
3Productivity
If STING agonists are developed for cancer immunotherapy, then tumor regression is achieved, but off-target inflammatory effects may occur
Solution Approach 1:
The patent introduces specific substituents at defined positions on the tricyclic core, creating local structural features that enhance tumor-selective STING activation. This local quality modification allows the compound to preferentially activate STING in the tumor microenvironment while minimizing systemic inflammatory responses.
Solution Approach 2:
The tricyclic compound acts as an intermediary that selectively delivers immunostimulatory signals to tumor-associated cells. The specific molecular structure serves as a mediator that enhances antigen-presenting cell activation and T cell responses in tumors while sparing normal tissues from excessive inflammatory activation.
Data Source
Figure 1~2
AI summary
Disclosed herein is an aryl tricyclic STING agonist compound having the structure of formula (I), and a preparation method thereof.